Even if focusing on currently uncurable conditions like cancer isn't a bad thing in itself, it means that a cure for cancer would be disastrous for the bottom line of biotech companies that follow this strategy. It's not just a different allocation of resources, it's an incentive to deprioritize cures in general. Any plan to maximize healthcare profit will result in perverse incentives, which is what those "knee-jerk Goldman Sachs is Evil" comments are largely criticizing. Obviously Goldman Sachs is stating the facts, but the assumption is that the choice with greater profitability is the correct one. That that assumption underlies medical research and development is the evil part.